OAKLAND, Calif. — Merck & Co., the pharmacology giant that manufactures the anti-inflammatory treatment montelukast aka Singulair, defeated product liability claims in a California federal court. Patients sued, alleging montelukast can cause neuropsychiatric events and homicidal thoughts, as the drug crosses the blood-brain barrier. The Singulair label warns users that this can happen, and nothing on the record suggests the label warnings are inadequate for physicians prescribing montelukast to adults.
Read the ruling **here and here.
Read our prior coverage here.
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.
Search Articles
